| $30.34 | $32.49 | 1,442,155 |
|---|---|---|
| Open Price | Prev. Close | Avg. Volume |
What is NantKwest's (NK) stock price and symbol?
What is NantKwest's stock symbol? NantKwest trades on the NASDAQ under the ticker symbol "NK." What is NantKwest's stock price today? One share of NK stock can currently be purchased for approximately $13.07.
Will NantKwest stock grow/rise/go up?
The NantKwest stock price is 33.900 USD today. Will NantKwest stock price grow / rise / go up? Yes. The NK stock price can go up from 33.900 USD to 59.284 USD in one year. Is it profitable to invest in NantKwest stock?
How much is a share of NK worth?
One share of NK stock can currently be purchased for approximately $5.92. How much money does NantKwest make? NantKwest has a market capitalization of $647.32 million and generates $40 thousand in revenue each year.
How did NantKwest's earnings compare to analysts'earnings estimates?
The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. NantKwest had a negative trailing twelve-month return on equity of 56.06% and a negative net margin of 76,658.58%.
How were NantKwest's earnings last quarter?
NantKwest, Inc. (NASDAQ:NK) released its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per shar...
Who are NantKwest's key executives?
NantKwest's management team includes the following people: Dr. Barry J. Simon , Pres, Chief Admin. Officer & Exec. Director (Age 56, Pay $454.44...
What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO?
14 employees have rated NantKwest CEO Dr. Patrick Soon-Shiong on Glassdoor.com . Dr. Patrick Soon-Shiong has an approval rating of 55% among NantK...
Who are some of NantKwest's key competitors?
Some companies that are related to NantKwest include Krystal Biotech (KRYS) , Revolution Medicines (RVMD) , Allogene Therapeutics (ALLO) , Immu...
What other stocks do shareholders of NantKwest own?
Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRN...
When did NantKwest IPO?
(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share....
What is NantKwest's stock symbol?
NantKwest trades on the NASDAQ under the ticker symbol "NK."
What is NantKwest's stock price today?
One share of NK stock can currently be purchased for approximately $3.39.
How much money does NantKwest make?
NantKwest (NASDAQ:NK) has a market capitalization of $370.68 million and generates $40 thousand in revenue each year. The biotechnology company ear...
ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness
ImmunityBio Awarded Seminal Patent on Natural Killer Cells
CULVER CITY, Calif., January 12, 2022--ImmunityBio, Inc.
AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE
CULVER CITY, Calif., January 04, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has been granted a U.S.
What Type Of Shareholders Own The Most Number of ImmunityBio, Inc. (NASDAQ:IBRX) Shares?
Amyris, Inc.
ImmunityBio Expands Vaccine Program to Accelerate Use of "Mix-and-Match" Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
The big shareholder groups in ImmunityBio, Inc. ( NASDAQ:IBRX ) have power over the company. Institutions often own...
Amyris takes bite out of sharks with Covid vaccine joint venture
CULVER CITY, Calif., November 18, 2021--ImmunityBio, Inc.
Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine
The East Bay company's synthetic biology work, coupled with RNA technology it has licensed, could help Patrick Soon-Shiong's ImmunityBio produce a Covid vaccine.
Barchart Technical Opinion
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced it has entered into a 50:50 joint venture arrangement with ImmunityBio, Inc.
Business Summary
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.
NantKwest
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc....
About NK
Some stock charts might currently not be supported. To try again, please refresh this page.
NantKwest Inc ( NK ) Stock Market info
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory.
Also on walletinvestor.com
Recommendations: Buy or sell NantKwest stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the NantKwest share forecasts, stock quote and buy / sell signals below.
